13,135 Shares in Guardant Health, Inc. $GH Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the second quarter, Holdings Channel reports. The firm bought 13,135 shares of the company’s stock, valued at approximately $1,971,000.

Other large investors have also recently added to or reduced their stakes in the company. EP Wealth Advisors LLC bought a new position in shares of Guardant Health in the second quarter valued at approximately $641,000. Ieq Capital LLC acquired a new stake in shares of Guardant Health in the second quarter worth $1,118,000. Callan Family Office LLC bought a new stake in shares of Guardant Health during the 2nd quarter worth $912,000. Green Alpha Advisors LLC bought a new stake in shares of Guardant Health during the 2nd quarter worth $385,000. Finally, Allworth Financial LP acquired a new position in Guardant Health in the 2nd quarter valued at $161,000. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, Director Ian T. Clark sold 14,180 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the completion of the transaction, the director owned 2,975 shares of the company’s stock, valued at approximately $472,787. This represents a 82.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Chris Freeman sold 63,605 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the completion of the sale, the insider owned 65,374 shares of the company’s stock, valued at approximately $11,086,122.92. The trade was a 49.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 521,818 shares of company stock valued at $77,539,233 in the last three months. Company insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on GH. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Evercore restated an “outperform” rating and set a $200.00 price target on shares of Guardant Health in a report on Monday, July 6th. BTIG Research raised their price target on Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Morgan Stanley lifted their price objective on Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Finally, UBS Group set a $150.00 price objective on Guardant Health in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Trading Up 1.7%

Shares of GH stock opened at $170.69 on Friday. The firm has a market capitalization of $22.91 billion, a P/E ratio of -48.91 and a beta of 1.60. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58. The firm’s fifty day simple moving average is $153.91 and its 200 day simple moving average is $118.69.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. Guardant Health’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same period last year, the company earned ($0.44) earnings per share. Equities research analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.